Selpercatinib (Retevmo)

Ingredients: Selpercatinib
Dosage Form: Oral tablets
Innovator’s Brand Name: Retevmo
Generic Brand Name: Selpacta
Generic Manufacturer: Ziska Pharma

Indications:
Selpercatinib is indicated for the treatment of metastatic RET fusion‑positive non‑small cell lung cancer, and for advanced or metastatic RET‑mutant or RET fusion‑positive thyroid cancer in patients aged 12 years and older who require systemic therapy.

Dosage and Administration:
For patients weighing < 50 kg, the recommended dose is 120 mg orally once daily. For patients weighing ≥ 50 kg, the recommended dose is 160 mg orally once daily, administered in two divided doses. If a dose is missed by more than 6 hours, skip that dose. Dose adjustment is required when coadministered with acid‑reducing agents.

Adverse Reactions:
Common adverse reactions include increased liver enzymes, hyperglycemia, decreased white blood cell count and serum albumin, hypocalcemia, dry mouth, diarrhea, renal impairment, hypertension, fatigue, peripheral edema, thrombocytopenia, hypercholesterolemia, rash, and hyponatremia.

Storage:
Store in a cool, dry place below 30 °C, protected from light, and keep out of reach of children.

Package Insert (Prescribing Information):

Download Link